Erratum: w-3 fatty acids for major depressive disorder in adults: An abridged Cochrane review (BMJ Open (2016) 6 (e010172) DOI: 10.1136/bmjopen-2015-010172);ω-3 fatty acids for major depressive disorder in adults: An abridged Cochrane review

BMJ Open

Volumn 6, Issue 3, 2016, Pages

  Appleton, Katherine M ^a   Sallis, Hannah M ^b,c   Perry, Rachel ^c,d   Ness, Andrew R ^c,d   Churchill, Rachel ^b  

^a BOURNEMOUTH UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; OMEGA 3 FATTY ACID; PLACEBO;

ADVERSE OUTCOME; ARTICLE; COMPARATIVE STUDY; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR DEPRESSION; META ANALYSIS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SUPPLEMENTATION; SYSTEMATIC REVIEW; ADULT; DEPRESSIVE DISORDER, MAJOR; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; FATTY ACIDS, OMEGA-3; HUMANS; TREATMENT OUTCOME;

EID: 84960403630     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-010172corr1     Document Type: Erratum

References (69)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th edn. Washington DC: American Psychiatric Association, 2013.
2. World Health Organization. Global Burden of Disease. http://www.who.int/healthinfo/global-burden-disease/gbd/en/index.html 1 Febuary 2014.
3. Haag M. Essential fatty acids and the brain. Can J Psychiatry 2003;48:195-203.
4. Ruxton CHS, Calder PC, Reed SC, et al. The impact of long chain n-3 polyunsaturated fatty acids on human health. Nutr Res Rev 2005;18:113-29.
5. Ma J, Folsom AR, Eckfeldt JH, et al. Short- and long-term repeatability of fatty acid composition of human plasma phospholipids and cholesterol esters. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Am J Clin Nutr 1995;62:572-8.
6. British Nutrition Foundation. BNF Briefing paper: n-3 fatty acids and health. London: British Nutrition Foundation, 1999.
7. James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr 2000;71:343s-8s.
8. Hibbeln JR. Fish consumption and major depression. Lancet 1998;351:1213.
9. Silvers KM, Scott KM. Fish consumption and self-reported physical and mental health status. Public Health Nutr 2002;5:427-31.
10. Tanskanen A, Hibblen JR, Hintikka J, et al. Fish consumption, depression, and suicidality in a general population. Arch Gen Psychiatry 2001;58:512-13.
11. Edwards R, Peet M, Shay J, et al. Depletion of docosahexaenoic acid in red blood cell membranes of depressive patients. Biochem Soc Trans 1998;26:S142.
12. Peet M, Murphy B, Shay J, et al. Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biol Psychiatry 1998;43:315-19.
13. Nemets B, Stahl Z, Belmaker RH. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry 2002;159:477-9.
14. Su KP, Huang SY, Chiu CC, et al. Omega-3 fatty acids in major depressive disorder-a preliminary double-blind placebo-controlled trial. Eur Neuropsychopharmacol 2003;13:267-71.
15. Frangou S, Lewis M, McCrone P. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. Br J Psychiatry 2006;188:46-50.
16. Stoll AL, Severus WE, Freeman MP, et al. Omega-3 fatty acids in bipolar disorder-a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 1999;56:407-12.
17. Hakkarainen R, Partonen T, Haukka J, et al. Is low dietary intake of omega-3 fatty acids associated with depression? Am J Psychiatry 2004;161:567-9.
18. Miyake Y, Sasaki S, Yokoyama T, et al. Risk of postpartum depression in relation to dietary fish and fat intake in Japan: the Osaka Maternal and Child Health Study. Psychol Med 2006;36:1727-35.
19. Appleton KM, Peters TJ, Hayward RC, et al. Depressed mood and n-3 polyunsaturated fatty acid intake from fish: non-linear or confounded association? Soc Psychiatry Psychiatr Epidemiol 2007;42:100-4.
20. Appleton KM, Gunnell D, Peters TJ, et al. No clear evidence of an associations between plasma concentrations of n-3 long chain polyunsaturated fatty acids and depressed mood in a non-clinical population. Prostaglandins Leukot Essent Fatty Acids 2008;78:337-42.
21. Browne JC, Scott KM, Silvers KM. Fish consumption in pregnancy and omega-3 status after birth are not associated with postnatal depression. J Affect Disord 2006;90:131-9.
22. Mamalakis G, Kiriakakis M, Tsibinos G, et al. Depression and adipose polyunsaturated fatty acids in an adolescent group. Prostaglandins Leukot Essent Fatty Acids 2004;71:289-94.
23. Grenyer BFS, Crowe T, Meyer B, et al. Fish oil supplementation in the treatment of major depression: a randomised double-blind placebo-controlled trial. Prog Neuro Psychopharmacol Biol Psychiatry 2007;31:1393-6.
24. Silvers KM, Woolley CC, Hamilton FC, et al. Randomised double-blind placebo-controlled trial of fish oil in the treatment of depression. Prostaglandins Leukot Essent Fatty Acids 2005;72:211-18.
25. Keck PE Jr, Mintz J, McElroy SL, et al. Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol Psychiatry 2006;60:1020-2.
26. Rogers PJ, Appleton KM, Kessler D, et al. No effect of n-3 long chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: a randomized controlled trial. Br J Nutr 2008;99:421-31.
27. Appleton KM, Hayward RC, Gunnell D, et al. Effects of n3 long chain polyunsaturated fatty acids on depressed mood: systematic review of published trials. Am J Clin Nutr 2006;84:1308-16.
28. Appleton KM, Rogers PJ, Ness AR. Is there a role for n-3 long-chain polyunsaturated fatty acids in the regulation of mood and behaviour? A review of the evidence to date from epidemiological studies, clinical studies and intervention trials. Nutr Res Rev 2008;21:13-41.
29. Appleton KM, Rogers PJ, Ness AR. Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood. Am J Clin Nutr 2010;91:757-70.
30. Lin PY, Su KP. A meta-analytic review of double-blind, placebo-controlled trials of anti-depressant efficacy of omega-3 fatty acids. J Clin Psychiatry 2007;68:1056-61.
31. Smith MA, Beilin LJ, Mori TA, et al. Essential fatty acids and mood: a systematic review of observational studies. Am J Food Nutr 2011;1:14-27.
32. Bloch MH, Hannestad J. Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis. Mol Psychiatry 2012;17:1272-82.
33. Grosso G, Pajak A, Marventano S, et al. Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive metaanalysis of randomized clinical trials. PLoS ONE 2014;9:e96905.
34. Martins JG. EPA but not DHA appears to be responsible for the efficacy of omega-3 LC-PUFA supplementation in depression: evidence from an updated meta-analysis of randomized controlled trials. Oleagineux Corps Gras Lipides 2011;18:188-98.
35. Sublette ME, Ellis SP, Geant AL, et al. Meta-analysis of the effects of eicosapentaenoic aicd (EPA) in clinical trials in depression. J Clin Psychiatry 2011;72:1577-84.
36. Appleton KM, Perry R, Sallis HM, et al. Omega-3 fatty acids for depression in adults. Cochrane Database Syst Rev 2015;(11): CD004692.
37. Appleton KM, Perry R, Sallis HM, et al. Omega-3 fatty acids for depression in adults. Cochrane Database Syst Rev 2014;(5): CD004692.
38. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. 5.1 edn. Chichester, UK: The Cochrane Collaboration & John Wiley & Sons, Ltd, 2011.
39. Deeks JJ, Altman DG, Bradbrun MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG, eds. Systematic reviews in health care: meta-analysis in context. London: BMJ Publishing Group, 2001:285-312.
40. Egger M, Davey Smith G. Principles of and procedures for systematic reviews. In: Egger M, Davey Smith G, Altman DG, eds. Systematic reviews in health care: meta-analysis in context. London: BMJ Publishing Group, 2001:23-42.
41. Sterne JAC, Egger M, Davey Smith G. Investigating and dealing with publication and other biases. In: Egger M, Davey Smith G, Altman DG, eds. Systematic reviews in health care: meta-analysis in context. London: BMJ Publishing Group, 2001:189-208.
42. Furukawa TA, Barbui C, Cipriani A, et al. Imputing missing standard deviations in meta-analyses can provide accurate results. J Clin Epidemiol 2006;59:7-10.
43. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58.
44. Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
45. Lucas M, Asselin G, Mérette C, et al. Ethyl-eicosapentaenoic acid for the treatment of psychological distress and depressive symptoms in middle-aged women: a double-blind, placebo-controlled, randomized clinical trial. Am J Clin Nutr 2009;89:641-51.
46. Coryell WH. Essential Fatty Acids for Major Depression. http://clinicaltrials.gov/show/NCT00256412 (Accessed 22 Jul. 2014).
47. Da Silva TM, Munhoz RP, Alvarez C, et al. Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot stud of omega-3 fatty-acid supplementation. J Affect Disord 2008;111:351-9.
48. Jazayeri S, Tehrani-Doost M, Keshavarz SA, et al. Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder. Aust N Z J Psychiatry 2008;42:192-8.
49. Mischoulon D, Nierenberg AA, Schettler PJ, et al. A double-blind randomized controlled clinical trial comparing eicosapentaenoic acid versus docosahexaenoic acid for depression. J Clin Psychiatry 2015;76:54-61.
50. Peet M, Horrobin DF. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 2002;59:913-19.
51. Bot M, Pouwer F, Assies J, et al. Eicosapentaenoic acid as an add-on to antidepressant medication for co-morbid major depression in patients with diabetes mellitus: a randomized, double-blind placebo-controlled study [ISRCTN30877831; NTR624]. J Affect Disord 2010;126:282-6.
52. Carney RM, Freedland KE, Rubin EH, et al. Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease: a randomized controlled trial. JAMA 2009;302:1651-7.
53. Gertsik L, Poland RE, Bresee C, et al. Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder. J Clin Psychopharmacol 2012;32:61-4.
54. Gharekhani A, Khatami MR, Dashti-Khavidaki S, et al. The effect of omega-3 fatty acids on depressive symptoms and inflammatory markers in maintenance hemodialysis patients: a randomized, placebo-controlled clinical trial. Eur J Clin Pharmacol 2014;70:655-65.
55. Gonzalez A, Mata S, Sanchez P, et al. Omega-3 fatty acids as adjunctive of antidepressant therapy and its effects on brain-derived neurotrophic factor in serum, monocytes and lymphocytes. Arch Venezolanos Farmacol Terapeutica 2011;30:72-8.
56. Lesperance F, Frasure-Smith N, St-Andre E, et al. The efficacy of omega-3 supplementation for major depression: a randomized controlled trial [ISRCTN47431149]. J Clin Psychiatry 2011;72:1054-62.
57. Marangell LB, Martinez JM, Zboyan HA, et al. A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am J Psychiatry 2003;160:996-8.
58. Mischoulon D, Papakostas GI, Dording CM, et al. A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder. J Clin Psychiatry 2009;70:1636-44.
59. Park Y, Park YS, Kim SH, et al. Supplementation of n-3 polyunsaturated fatty acids for major depressive disorder: a randomized double-blind 12-week placebo-controlled trial in Korea. Ann Nutr Metab 2015;66:141-8.
60. Rondanelli M, Giacosa A, Opizzi A, et al. Effect of omega-3 fatty acids supplementation on depressive symptoms and on health-related quality of life in the treatment of elderly women with depression: a double-blind, placebo-controlled, randomized clinical trial. J Am Coll Nutr 2010;29:55-64.
61. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9.
62. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatr 1960;23:56-62.
63. Beck AT, Steer RA. Beck Depression Inventory Manual. San Antonio, Texas: Psychological Corporation, 1987.
64. Yesvage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982;17:37-49.
65. National Institute for Clinical Excellence. Depression: management of depression in primary and secondary care. London, England: National Institute for Clinical Excellence, 2004.
66. Lin PY, Mischoulon D, Freeman MP, et al. Are omega-3 fatty acids anti-depressants or just mood-improving agents? The effect depends upon diagnosis, supplement preparation, and severity of depression. Mol Psychiatry 2012;17:1161-3; author reply 1163-7.
67. Fountoulakis KN, Veroniki AA, Siamouli M, et al. No role for initial severity on the efficacy of antidepressants: results of a multi-meta-analysis. Ann Gen Psychiatry 2013;12:26.
68. Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008;5:e45.
69. Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008;358:252-60.